Windtree Therapeutics Delisted from Nasdaq for Rule Violation

Windtree Therapeutics will be delisted from Nasdaq after failing to meet Listing Rule 5550(a)(2), requiring a minimum $1 bid price. The official notification was confirmed in SEC filings submitted on August 20, 2025.

The biotech firm, led by CEO Jed Latkin, failed to maintain the necessary stock price. The company’s shares will move to OTC markets, following a 76% price drop in a day and a 99% decline over the year.

As Windtree transitions to OTC trading, investor access is likely to see reduced liquidity and transparency. The delisting may further impact investor confidence and introduces potential market volatility surrounding their future operations.

Despite these shifts, BNB (Binance Coin), used in their treasury, reached a record high above $880. This indicates no immediate ripple effects on broader cryptocurrency markets or significant alterations in BNB educational trends.

The biotech sector routinely faces such delistings when failing Nasdaq’s compliance standards. Historically, affected firms rarely regain investor confidence unless major restructuring occurs, as seen in similar past industry events.

Insights reveal possible future volatility for firms using similar treasury strategies and regulatory scrutiny. Windtree’s case highlights the significance of maintaining market compliance for investors’ financial security and market integrity.

“Windtree will maintain its reporting obligations despite the market downgrade.” — Jed Latkin, CEO, Windtree Therapeutics.